HIV / Virology
Globally, the number of people living with HIV continues to grow, from 35 million in 2001 to 38 million in 2003. Just under five million people throughout the world became infected with HIV in 2003, greater than any year since the start of the epidemic.
Tibotec Therapeutics is dedicated to identifying and ensuring the successful commercialization of innovative products that can significantly benefit people affected by HIV. The company's goal is to significantly contribute to changing the course of HIV infection, and help address serious unmet needs among people living with HIV.
Currently, Tibotec Therapeutics markets the protease inhibitor PREZISTA™(darunavir).
Our Capabilities
Being a leader also means taking initiative. It means having a start-up mentality and knowing how to maximize resources. It means partnering and devising creative solutions, and driving toward competitive advantage. Our strength comes from distinctive advantages, like the energy of an entrepreneurial business, backed by the power of a global healthcare organization.
Tibotec Therapeutics draws on the scientific expertise and resources of several sister organizations, including Tibotec Pharmaceuticals Ltd, ALZA Corporation, Centocor Research & Development Inc. and TransForm Pharmaceuticals, Inc., as well as partnerships with leading external academic institutions and biopharmaceutical companies.
For medical professionals: leading the way in virology therapeutics means providing the best medicines for patients and health care providers.